Amgen, a pharmaceutical company based in Thousand Oaks, California announced that the FDA has accepted the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. Kyprolis is a selective proteasome inhibitor, originally developed by Onyx Pharmaceuticals, now a subsidiary of Amgen.  It was approved by the FDA as a third-line treatment for multiple myeloma.  Amgen is currently sponsoring clinical trials hoping to convert this drug a second-line treatment for the same indication.

Related Links:

http://www.amgen.com/media/media_pr_detail.jsp?releaseID=2030473